CN117580952A - 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 - Google Patents
双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 Download PDFInfo
- Publication number
- CN117580952A CN117580952A CN202280046071.8A CN202280046071A CN117580952A CN 117580952 A CN117580952 A CN 117580952A CN 202280046071 A CN202280046071 A CN 202280046071A CN 117580952 A CN117580952 A CN 117580952A
- Authority
- CN
- China
- Prior art keywords
- nucleotide
- nucleotide sequence
- double
- stranded oligonucleotide
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021108074639 | 2021-07-16 | ||
| CN202110807463 | 2021-07-16 | ||
| PCT/CN2022/105340 WO2023284763A1 (zh) | 2021-07-16 | 2022-07-13 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117580952A true CN117580952A (zh) | 2024-02-20 |
Family
ID=84919035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280046071.8A Pending CN117580952A (zh) | 2021-07-16 | 2022-07-13 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240309378A1 (https=) |
| EP (1) | EP4372086A1 (https=) |
| JP (1) | JP2024528634A (https=) |
| CN (1) | CN117580952A (https=) |
| TW (1) | TW202308665A (https=) |
| WO (1) | WO2023284763A1 (https=) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118147134A (zh) * | 2023-11-06 | 2024-06-07 | 北京悦康科创医药科技股份有限公司 | 靶向调控PCSK9基因表达的siRNA及其应用 |
| CN118516348A (zh) * | 2024-07-23 | 2024-08-20 | 深川生物科技(山东)股份公司 | 单链核酸或双链核酸及在制备治疗杜氏肌营养不良的药物中的应用 |
| CN118995718A (zh) * | 2024-10-24 | 2024-11-22 | 苏州炫景生物科技有限公司 | 含有末端核苷酸修饰的双链寡核苷酸及其在抑制agt基因表达中的应用 |
| CN119410644A (zh) * | 2025-01-08 | 2025-02-11 | 北京安龙生物医药有限公司 | 修饰的双链寡核苷酸及其缀合物和组合物 |
| WO2026026776A1 (zh) * | 2024-08-01 | 2026-02-05 | 北京尧景基因技术有限公司 | 抑制APP基因表达的siRNA及其缀合物和应用 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019006455A1 (en) | 2017-06-30 | 2019-01-03 | Solstice Biologics, Ltd. | AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF |
| WO2020233651A1 (zh) * | 2019-05-22 | 2020-11-26 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP2025520796A (ja) * | 2022-06-27 | 2025-07-03 | 大睿生物 | アポリポタンパク質C3発現を阻害するsiRNA |
| WO2024140101A1 (zh) * | 2022-12-28 | 2024-07-04 | 北京炫景瑞医药科技有限公司 | 修饰的双链寡核苷酸分子、修饰的双链寡核苷酸缀合物及其用途 |
| TW202508607A (zh) * | 2023-05-19 | 2025-03-01 | 大陸商北京炫景瑞醫藥科技有限公司 | 雙股寡核苷酸及其共軛物和用途 |
| TW202509216A (zh) * | 2023-07-14 | 2025-03-01 | 大陸商北京安龍生物醫藥有限公司 | 靶向血管收縮素原的寡核苷酸及其用途 |
| WO2025031301A1 (zh) * | 2023-08-08 | 2025-02-13 | 苏州炫景生物科技有限公司 | Fto抑制剂组合物及其应用 |
| CN117384907B (zh) * | 2023-12-11 | 2024-03-29 | 上海鼎新基因科技有限公司 | 抑制PCSK9表达的siRNA分子及其应用 |
| WO2026052079A1 (zh) * | 2024-09-07 | 2026-03-12 | 苏州瑞博生物技术股份有限公司 | 寡核苷酸、寡核苷酸缀合物及组合物和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2626690A1 (en) * | 2005-11-09 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor v leiden mutant gene |
| AU2007275365A1 (en) * | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) |
| WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
| CN102140458B (zh) | 2010-01-29 | 2013-05-22 | 苏州瑞博生物技术有限公司 | 小干扰核酸和药物组合物及其制药应用 |
| US20120136073A1 (en) | 2010-11-15 | 2012-05-31 | Life Technologies Corporation | Amine-Containing Transfection Reagents and methods for making and using same |
| AU2013299717B2 (en) | 2012-08-06 | 2018-06-28 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated RNA agents and process for their preparation |
| JP6702862B2 (ja) | 2013-07-11 | 2020-06-03 | アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. | オリゴヌクレオチド−リガンドコンジュゲートおよびそれらの調製方法 |
| US20170081667A1 (en) * | 2014-03-13 | 2017-03-23 | Kyowa Hakko Kirin Co., Ltd. | Nucleic acid that inhibits expression of irf5 |
| CA3083968C (en) | 2017-12-01 | 2024-04-23 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
| WO2019105435A1 (zh) * | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105437A1 (zh) * | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110945130B (zh) * | 2017-12-01 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7365052B2 (ja) * | 2017-12-01 | 2023-10-19 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| EP3732185B1 (en) | 2017-12-29 | 2025-02-26 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
| US12496347B2 (en) * | 2018-12-28 | 2025-12-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
-
2022
- 2022-07-13 US US18/576,589 patent/US20240309378A1/en active Pending
- 2022-07-13 CN CN202280046071.8A patent/CN117580952A/zh active Pending
- 2022-07-13 EP EP22841396.9A patent/EP4372086A1/en active Pending
- 2022-07-13 WO PCT/CN2022/105340 patent/WO2023284763A1/zh not_active Ceased
- 2022-07-13 JP JP2024502054A patent/JP2024528634A/ja active Pending
- 2022-07-15 TW TW111126699A patent/TW202308665A/zh unknown
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118147134A (zh) * | 2023-11-06 | 2024-06-07 | 北京悦康科创医药科技股份有限公司 | 靶向调控PCSK9基因表达的siRNA及其应用 |
| CN118147134B (zh) * | 2023-11-06 | 2025-02-25 | 北京悦康科创医药科技股份有限公司 | 靶向调控PCSK9基因表达的siRNA及其应用 |
| CN118516348A (zh) * | 2024-07-23 | 2024-08-20 | 深川生物科技(山东)股份公司 | 单链核酸或双链核酸及在制备治疗杜氏肌营养不良的药物中的应用 |
| WO2026026776A1 (zh) * | 2024-08-01 | 2026-02-05 | 北京尧景基因技术有限公司 | 抑制APP基因表达的siRNA及其缀合物和应用 |
| CN118995718A (zh) * | 2024-10-24 | 2024-11-22 | 苏州炫景生物科技有限公司 | 含有末端核苷酸修饰的双链寡核苷酸及其在抑制agt基因表达中的应用 |
| CN119410644A (zh) * | 2025-01-08 | 2025-02-11 | 北京安龙生物医药有限公司 | 修饰的双链寡核苷酸及其缀合物和组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202308665A (zh) | 2023-03-01 |
| US20240309378A1 (en) | 2024-09-19 |
| EP4372086A1 (en) | 2024-05-22 |
| WO2023284763A1 (zh) | 2023-01-19 |
| JP2024528634A (ja) | 2024-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117580952A (zh) | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 | |
| KR102756073B1 (ko) | 이중-가닥 올리고뉴클레오티드, 조성물 및 이중-가닥 올리고뉴클레오티드를 포함하는 접합체, 그의 제조 방법 및 그의 용도 | |
| CN113227376B (zh) | 核酸、药物组合物与缀合物及制备方法和用途 | |
| CN115677810B (zh) | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 | |
| EP3903830A1 (en) | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof | |
| EP3974530A1 (en) | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | |
| CN113614230B (zh) | 核酸、药物组合物与缀合物及制备方法和用途 | |
| CN117580953B (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| CN114685585B (zh) | 核苷酸序列、双链寡核苷酸、药物组合物与缀合物及制备方法和用途 | |
| CN118202049A (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| WO2022143531A1 (zh) | 一种核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途 | |
| CN114686482B (zh) | 一种核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途 | |
| CN118360282A (zh) | 核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| WO2023213284A9 (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| WO2023116764A1 (zh) | 一种核酸、含有该核酸的组合物与缀合物及其用途 | |
| CN120769912A (zh) | 一种药物组合物及其用途 | |
| WO2025140402A1 (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| WO2024188173A1 (zh) | 一种核酸、含有该核酸的组合物与缀合物及其用途 | |
| WO2023088455A1 (zh) | 一种核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途 | |
| WO2026052079A1 (zh) | 寡核苷酸、寡核苷酸缀合物及组合物和用途 | |
| WO2026052078A1 (zh) | 寡核苷酸、寡核苷酸缀合物及组合物和用途 | |
| WO2026052021A1 (zh) | 寡核苷酸、寡核苷酸缀合物及组合物和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40100846 Country of ref document: HK |